StockUS listing USILMNNASDAQHealthcareQuality Compounder

Illumina Inc(ILMN) Stock Analysis | Healthcare

USD --+0.00%
Reward58Moderate
Risk45Moderate
75%Data
Strong 18% profit margin
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 42.00Bn
Reward Ratingⓘ58 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ45 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ILMN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Illumina Inc?

provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

AI Brief Pro

The brief on Illumina Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Illumina Inc?

provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 42.00B, and a P/E ratio of 51.9x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (58)

Similar stocks to compare

A short list of Diagnostics & Research names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDiagnostics & Research
P/E Ratio51.8974
Beta1.416
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
12,370 shares
$275k
1200 shares
$24k
9-12months
1323 shares
$44k
1500 shares
$61k

Openbook research

Articles mentioning ILMN

1